<DOC>
	<DOCNO>NCT01941550</DOCNO>
	<brief_summary>This study aim evaluate efficacy regard response rate metastasis-free survival time cabazitaxel neoadjuvant treatment patient high risk prostate cancer .</brief_summary>
	<brief_title>Neoadjuvant Chemotherapy With Cabazitaxel</brief_title>
	<detailed_description>Patients treat 6 cycle Cabazitaxel 25 mg/m2 every three week extend radical prostatectomy extend pelvic lymphadenectomy 4 week completion chemotherapy . Multiparametric MRI perform baseline , 3 cycle 6 cycle . If evidence clinical progression 3rd cycle , patient remove study give local therapy , include radical prostatectomy external beam radiotherapy , discretion patient 's physician . If patient evidence response , continue treatment total 6 cycle . If multiparametric MRI demonstrate stable disease individual risk-benefit analysis perform regard continue stop neoadjuvant treatment since definition stable disease include patient ≤ 20 % tumour shrinkage tumour progression</detailed_description>
	<criteria>Surgically resectable high risk prostate cancer 5year relapse probability ≥ 60 % accord Kattan preoperative nomogram ( cancer 2009 , 115 : 10051010 ) prior therapy prostate cancer androgen deprivation therapy , radiation therapy , chemotherapy ECOG performance status 01 No evidence active infection Hemoglobin &gt; 9.0 g/dL Absolute neutrophil count &gt; 1.5 x 109/L , Platelet count &gt; 100 x 109/L , AST/SGOT and/or ALT/SGPT &lt; 2.5 x ULN ; Total bilirubin &lt; 1.0 x ULN , Serum creatinine &lt; 1.5 x ULN . If creatinine 1.0 1.5 x ULN , creatinine clearance calculate accord CKDEPI formula patient creatinine clearance &lt; 60 mL/min exclude ) Patient information signature inform consent Male ≥ 18 year Patients reproductive age must take appropriate contraceptive precaution 6 month end participation study Evidence lymph node , visceral bone metastases previous major intrapelvic surgery previous radiation therapy small pelvis type malignancy within last 5 year except basalioma nonmuscle invasive urothelial cancer urinary bladder previous chemotherapy taxanes ( docetaxel , paclitaxel , cabazitaxel ) indication Hypersensitivity active substance excipients Known suspected brain metastasis leptomeningeal metastasis Active symptomatic viral hepatitis chronic liver disease Serious uncontrolled coexistent nonmalignant disease , include active uncontrolled infection</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>untreated , high risk prostate cancer</keyword>
</DOC>